Prevalence and clinical significance of visible oral lesions in patients with Fanconi Anemia at risk for head and neck cancer.
Prevalence and clinical significance of visible oral lesions in patients with Fanconi Anemia at risk for head and neck cancer. Curr Drug Targets. 2017 May 24;: Authors: Velleuer E, Dietrich R, Frohnmayer A, Pomjanski N, Hays LE, Biesterfeld S Abstract Fanconi anemia is a genetic bone marrow failure syndrome, variably associated with congenital anomalies and a sharply increased risk for epithelial malignancies. During the past 20 years, hematopoietic stem cell transplantation (HSCT) has dramatically improved survival. However, compared to the general population, FA patients are at greatly increased risk, and at a much younger age, for squamous cell carcinomas (SCC) of the oral cavity, esophagus and the anogenital region. The relative risk and age of onset appears to negatively correlate with HSCT in FA patients. Due to the underlying defect in DNA crosslink repair, standard chemotherapy protocols cannot be used in FA patients with SCCs. Therefore, early detection of precancerous lesions is the most promising option for long-term cure and survival. Based on oral screenings of 300 patients, we report here on the prevalence of visible oral lesions as potential precursors of oral SCCs in FA patients. PMID: 28545381 [PubMed - as supplied by publisher]
There is an urgent need to share expertise and offer emergency guidance for breast radiation therapy (RT) during the COVID-19 (Coronavirus) pandemic. As per the World Health Organisation (WHO) statement, our aim and obligation should be “to stop, contain, control, delay and reduce the impact of this virus at every opportunity”. In our roles as healthcare professionals and/or breast cancer experts this translates to minimising exposure of our patients to COVID-19 without compromising oncological outcome.
Purpose: The availability of novel imaging modalities (NIM) in prostate cancer (PCa) has overtaken the evidence informing their use. The recent EORTC consensus statement on modern imaging recognises the need for large-scale clinical trials of novel imaging . The UK environment is well placed to conduct such trials; the NCRI prostate cancer CSG wished to benchmark current UK imaging availability and practice to inform future national trials.
Purpose: The role of pelvic nodal irradiation in prostate cancer remains controversial. Nevertheless, many high-risk patients are treated with prostate and pelvis radiotherapy in addition to androgen deprivation therapy (ADT) . A recent retrospective study  and data from the UK Stampede control arm  suggest that radiotherapy may be of benefit to node positive patients. The aim of our study was to document outcomes in patients with node positive prostate cancer treated with pelvic nodal radiotherapy in a UK cancer centre.
Purpose: Relapsed or progressive prostate cancer frequently manifests as consecutive PSA rises long before disease is clinically detectable. Imaging with novel radiotracers targeting prostate-specific membrane antigen (PSMA) has been shown to be more sensitive in identifying the site of disease at lower PSA levels compared with conventional imaging, which may provide increased opportunity for salvage therapy, more aggressive local management of oligometastatic disease or increased confidence in proceeding with systemic therapy .
Purpose: To assess the benefits and risks of co-administering maintenance prednisolone with docetaxel and androgen-deprivation therapy (ADT) in hormone sensitive metastatic prostate cancer (HSMPC).
Purpose: Immune checkpoint inhibitors (ICI) are now standard of care for advanced urothelial carcinoma (UC) that have failed platinum therapy. Atezolizumab and pembrolizumab are also approved in the first line setting for patients who are cisplatin-ineligible and are PD-L1 positive. This retrospective observational study aimed to describe the safety and efficacy of the ICI pembrolizumab in the real world setting at Guy ’s Hospital.
Purpose: As doctors we are required to take consent for radiotherapy; we typically take written consent . We must tell a patient if a treatment might result in a serious adverse outcome, even if the likelihood is very small . As many cancer centres move towards tumour site-specific consent forms for prostate radiotherapy we wanted to ascertain if there was consensus.
In this study, we describe our experience with both drugs at the Diana Princess of Wales Hospital (DPoW), Grimsby.
Purpose: Synchronous chemotherapy with mitomycin C and 5-FU with radiotherapy may have an additional benefit over radiotherapy alone . We looked into the rate of recurrence and median overall survival between these two groups of patients.
Purpose: The use of FDG PET has become more readily available over the past 15 years. It can be used to aid initial staging of testicular tumours and also assess the response to treatment in the metastatic setting, especially as residual masses are frequently seen after chemotherapy. There have been some recent concerns that FDG PET used to assess for residual disease may have a low positive predictive value . A retrospective audit was carried out to look at the performance of FDG PET in seminoma patients treated at the Edinburgh Cancer Centre.
More News: Anemia | Bone Marrow Failure Syndrome (BMFS) | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Drugs & Pharmacology | Epithelial Cancer | Esophagus Cancer | Faconi Anemia | Gastroschisis Repair | Genetics | Head and Neck Cancer | Nutrition | Oral Cancer | Oral Cavity Cancer | Squamous Cell Carcinoma | Stem Cell Therapy | Stem Cells | Transplants